CANFCan-Fite BioPharma Ltd.

NYSE canfite.com


$ 2.30 $ -0.01 (-0.43 %)    

Thursday, 29-Aug-2024 11:36:16 EDT
QQQ $ 471.39 $ -1.32 (-0.28 %)
DIA $ 413.79 $ -0.55 (-0.13 %)
SPY $ 558.50 $ -1.68 (-0.3 %)
TLT $ 97.60 $ 0.05 (0.05 %)
GLD $ 233.12 $ 1.12 (0.48 %)
$ 2.31
$ 2.30
$ 2.31 x 100
-- x --
$ 2.30 - $ 2.30
$ 1.81 - $ 4.69
13,351
na
62.81M
$ 0.70
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 can-fite-biopharma-1h-eps-000-same-yoy-revenue-316k-down-from-392k-yoy

Financial ResultsRevenues for the six months ended June 30, 2024 were $0.32 million compared to revenues of $0.39 million for t...

 ef-hutton-initiates-coverage-on-can-fite-biofarma-with-buy-rating-announces-price-target-of-10

EF Hutton analyst Jason Kolbert initiates coverage on Can Fite Biofarma (AMEX:CANF) with a Buy rating and announces Price Ta...

 can-fite-submits-application-to-fda-for-orphan-drug-designation-for-its-drug-candidate-namodenoson-in-the-treatment-of-pancreatic-carcinoma

Can-Fite plans to start shortly a Phase IIa clinical study that will be a multicenter open-label trial in patients with advance...

 can-fite-biopharma-announced-that-a-patient-with-liver-decompensated-cirrhosis-who-was-treated-with-namodenoson-at-the-soroka-medical-center-in-israel-under-compassionate-use-showed-an-improvement-in-liver-indices

This Drug Candidate Is Currently Used In A Pivotal Phase 3 Study For Patients With Advanced Liver Cancer And A Phase 2b Study F...

 can-fite-announces-new-findings-on-namodenosons-dual-anti-cancer-and-liver-protective-effects

Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule dr...

 can-fite-biopharma-says-its-phase-3-study-for-namodenoson-for-advanced-liver-cancer-is-31-recruiting-medical-centers-namodenoson-has-orphan-drug-status-from-fda-and-european-medicines-agency-and-fda-fast-track-status

A compassionate use program has also been ongoing in Israel and Romania. 

 hc-wainwright--co-reiterates-buy-on-can-fite-biofarma-maintains-18-price-target

HC Wainwright & Co. analyst Vernon Bernardino reiterates Can Fite Biofarma (AMEX:CANF) with a Buy and maintains $18 pric...

 can-fite-received-notice-of-allowance-from-the-european-patent-office-for-the-treatment-of-erectile-dysfunction-with-cf602

Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE:CANF), a biotechnology company advancing a pipeline of proprietary small molecule dru...

 can-fite-biopharma-announced-it-published-an-article-in-the-experimental-and-therapeutic-medicine-journal-long-term-complete-response-to-namodenoson-in-liver-cancer-with-child-pugh-b-cirrhosis

The Patient Participated In The Phase Ii Liver Cancer Study And Has Been Treated With Namodenoson For >7 Years Under Compass...

 can-fites-namodenoson-featured-in-biomedicines-for-liver-cancer-and-mash-treatment-insights

Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule dr...

 can-fite-biopharma-submits-fda-with-an-ind-application-to-conduct-phase-iib-clinical-trial-of-namodenoson-in-mash-patients

Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE:CANF), a biotechnology company advancing a pipeline of proprietary small molecule dru...

 can-fite-biofarma-fy-gaap-eps-001-same-yoy-sales-74300k-down-from-81000k-yoy

Can Fite Biofarma (AMEX:CANF) reported quarterly losses of $(0.01) per share. This is unchanged from the same period last year....

 can-fite-expands-the-out-licensing-deal-with-ewopharma-to-include-the-pancreatic-cancer-indication

Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE:CANF), a biotechnology company advancing a pipeline of proprietary small molecule dru...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION